Hypoxia-induced miR-210 in epithelial ovarian cancer enhances cancer cell viability via promoting proliferation and inhibiting apoptosis

Li,Li'an; Huang,Ke; You,Yanqin; Fu,Xiaoyu; Hu,Lingyun; Song,Lei; Meng,Yuanguang

doi:10.3892/ijo.2014.2368

Hypoxia-induced miR-210 in epithelial ovarian cancer enhances cancer cell viability via promoting proliferation and inhibiting apoptosis

Authors:
- Li'an Li
- Ke Huang
- Yanqin You
- Xiaoyu Fu
- Lingyun Hu
- Lei Song
- Yuanguang Meng
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Chinese PLA General Hospital, Beijing 100853, P.R. China
Published online on: April 4, 2014 https://doi.org/10.3892/ijo.2014.2368
Pages: 2111-2120

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

miR-210 is upregulated in a HIF-1α-dependent way in several types of cancers. In addition, upregulated miR-210 promotes cancer proliferation, via its anti-apoptotic effects. It is blind to the regulation of miR-210 under hypoxia conditions for ovarian cancer cells and to the effect of miR-210 on ovarian cancer growth. In the present study, we determined the expression of miR-210 in epithelial ovarian cancer specimens, and in ovarian cancer cell lines under hypoxia conditions, and determined in detail the effect of miR-210 overexpression on tumor cell proliferation, and the possible mechanisms of tumor growth by miR-210 regulation. It was shown that miR-210 expression is upregulated, in response to hypoxia conditions in epithelial ovarian cancer specimens as well as epithelial ovarian cancer cell lines, with an association to HIF-1α overexpression. Furthermore, upregulated miR-210 promoted tumor growth in vitro via targeting PTPN1 and inhibiting apoptosis. Therefore, our findings shed light on the mechanism of ovarian cancer adaptation to hypoxia.

View Figures

View References

1.	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2.	Colombo N, Van Gorp T, Parma G, et al: Ovarian cancer. Crit Rev Oncol Hematol. 60:159–179. 2006. View Article : Google Scholar
3.	Moss C and Kaye SB: Ovarian cancer: progress and continuing controversies in management. Eur J Cancer. 38:1701–1707. 2002. View Article : Google Scholar : PubMed/NCBI
4.	Hockel M and Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 93:266–276. 2001. View Article : Google Scholar : PubMed/NCBI
5.	Dang CV and Semenza GL: Oncogenic alterations of metabolism. Trends Biochem Sci. 24:68–72. 1999. View Article : Google Scholar
6.	Harris AL: Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
7.	Cummins EP and Taylor CT: Hypoxia-responsive transcription factors. Pflugers Arch. 450:363–371. 2005. View Article : Google Scholar : PubMed/NCBI
8.	Licausi F, Weits DA, Pant BD, Scheible WR, Geigenberger P and van Dongen JT: Hypoxia responsive gene expression is mediated by various subsets of transcription factors and miRNAs that are determined by the actual oxygen availability. New Phytol. 190:442–456. 2011. View Article : Google Scholar : PubMed/NCBI
9.	Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar
10.	Christofk HR, Vander Heiden MG, Harris MH, et al: The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 452:230–233. 2008. View Article : Google Scholar : PubMed/NCBI
11.	Wang GL, Jiang BH, Rue EA and Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O₂ tension. Proc Natl Acad Sci USA. 92:5510–5514. 1995. View Article : Google Scholar : PubMed/NCBI
12.	Pouyssegur J, Dayan F and Mazure NM: Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 441:437–443. 2006. View Article : Google Scholar : PubMed/NCBI
13.	Kaelin WG Jr and Ratcliffe PJ: Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 30:393–402. 2008. View Article : Google Scholar : PubMed/NCBI
14.	Blancher C, Moore JW, Talks KL, Houlbrook S and Harris AL: Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res. 60:7106–7113. 2000.
15.	Zhong H, De Marzo AM, Laughner E, et al: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59:5830–5835. 1999.PubMed/NCBI
16.	Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI
17.	Pralhad T, Madhusudan S and Rajendrakumar K: Concept, mechanisms and therapeutics of angiogenesis in cancer and other diseases. J Pharm Pharmacol. 55:1045–1053. 2003. View Article : Google Scholar : PubMed/NCBI
18.	Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature. 407:249–257. 2000. View Article : Google Scholar : PubMed/NCBI
19.	Semenza GL: HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med. 8:S62–S67. 2002. View Article : Google Scholar : PubMed/NCBI
20.	Chi JT, Wang Z, Nuyten DS, et al: Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med. 3:e472006. View Article : Google Scholar : PubMed/NCBI
21.	Imai T, Horiuchi A, Wang C, et al: Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am J Pathol. 163:1437–1447. 2003. View Article : Google Scholar : PubMed/NCBI
22.	Horiuchi A, Imai T, Shimizu M, et al: Hypoxia-induced changes in the expression of VEGF, HIF-1 alpha and cell cycle-related molecules in ovarian cancer cells. Anticancer Res. 22:2697–2702. 2002.PubMed/NCBI
23.	Horiuchi A, Hayashi T, Kikuchi N, et al: Hypoxia upregulates ovarian cancer invasiveness via the binding of HIF-1alpha to a hypoxia-induced, methylation-free hypoxia response element of S100A4 gene. Int J Cancer. 131:1755–1767. 2012. View Article : Google Scholar : PubMed/NCBI
24.	Osada R, Horiuchi A, Kikuchi N, et al: Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma. Hum Pathol. 38:1310–1320. 2007.
25.	Ambros V: MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell. 113:673–676. 2003. View Article : Google Scholar : PubMed/NCBI
26.	Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
27.	Brennecke J, Hipfner DR, Stark A, Russell RB and Cohen SM: Bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell. 113:25–36. 2003. View Article : Google Scholar : PubMed/NCBI
28.	Reinhart BJ, Slack FJ, Basson M, et al: The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 403:901–906. 2000. View Article : Google Scholar : PubMed/NCBI
29.	Jay C, Nemunaitis J, Chen P, Fulgham P and Tong AW: miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol. 26:293–300. 2007. View Article : Google Scholar : PubMed/NCBI
30.	Yu SL, Chen HY, Yang PC and Chen JJ: Unique microRNA signature and clinical outcome of cancers. DNA Cell Biology. 26:283–292. 2007. View Article : Google Scholar : PubMed/NCBI
31.	Qiang R, Wang F, Shi LY, et al: Plexin-B1 is a target of miR-214 in cervical cancer and promotes the growth and invasion of HeLa cells. Int J Biochem Cell Biol. 43:632–641. 2011. View Article : Google Scholar : PubMed/NCBI
32.	Au Yeung CL, Tsang TY, Yau PL and Kwok TT: Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway. Oncogene. 30:2401–2410. 2011.
33.	Xu CX, Xu M, Tan L, et al: MicroRNA miR-214 regulates ovarian cancer cell stemness by targeting p53/Nanog. J Biol Chem. 287:34970–34978. 2012. View Article : Google Scholar : PubMed/NCBI
34.	Ye G, Fu G, Cui S, et al: MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance. J Cell Sci. 124:359–368. 2011. View Article : Google Scholar : PubMed/NCBI
35.	Vecchione A, Belletti B, Lovat F, et al: A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proc Natl Acad Sci USA. 110:9845–9850. 2013. View Article : Google Scholar : PubMed/NCBI
36.	Mutharasan RK, Nagpal V, Ichikawa Y and Ardehali H: microRNA-210 is upregulated in hypoxic cardiomyocytes through Akt- and p53-dependent pathways and exerts cyto-protective effects. Am J Physiol Heart Circ Physiol. 301:H1519–H1530. 2011. View Article : Google Scholar : PubMed/NCBI
37.	Biswas S, Roy S, Banerjee J, et al: Hypoxia inducible microRNA 210 attenuates keratinocyte proliferation and impairs closure in a murine model of ischemic wounds. Proc Natl Acad Sci USA. 107:6976–6981. 2010. View Article : Google Scholar : PubMed/NCBI
38.	Merlo A, de Quiros SB, Secades P, et al: Identification of a signaling axis HIF-1alpha/microRNA-210/ISCU independent of SDH mutation that defines a subgroup of head and neck paragangliomas. J Clin Endocrinol Metab. 97:E2194–E2200. 2012. View Article : Google Scholar : PubMed/NCBI
39.	Wang H, Bian S and Yang CS: Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1alpha. Carcinogenesis. 32:1881–1889. 2011. View Article : Google Scholar : PubMed/NCBI
40.	Camps C, Buffa FM, Colella S, et al: hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res. 14:1340–1348. 2008. View Article : Google Scholar : PubMed/NCBI
41.	Gou D, Ramchandran R, Peng X, et al: miR-210 has an anti-apoptotic effect in pulmonary artery smooth muscle cells during hypoxia. Am J Physiol Lung Cell Mol Physiol. 303:L682–L691. 2012. View Article : Google Scholar : PubMed/NCBI
42.	Fasanaro P, D’Alessandra Y, Di Stefano V, et al: MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem. 283:15878–15883. 2008. View Article : Google Scholar : PubMed/NCBI
43.	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
44.	Kim SW, Li Z, Moore PS, et al: A sensitive non-radioactive northern blot method to detect small RNAs. Nucleic Acids Res. 38:e982010. View Article : Google Scholar : PubMed/NCBI
45.	Greijer AE and van der Wall E: The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol. 57:1009–1014. 2004. View Article : Google Scholar : PubMed/NCBI
46.	Carmeliet P, Dor Y, Herbert JM, et al: Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 394:485–490. 1998. View Article : Google Scholar : PubMed/NCBI
47.	Moritz W, Meier F, Stroka DM, et al: Apoptosis in hypoxic human pancreatic islets correlates with HIF-1alpha expression. FASEB J. 16:745–747. 2002.PubMed/NCBI
48.	Zhu P, Ning Y, Yao L, Chen M and Xu C: The proliferation, apoptosis, invasion of endothelial-like epithelial ovarian cancer cells induced by hypoxia. J Exp Clin Cancer Res. 29:1242010. View Article : Google Scholar : PubMed/NCBI
49.	Sangwan V, Paliouras GN, Cheng A, Dube N, Tremblay ML and Park M: Protein-tyrosine phosphatase 1B deficiency protects against Fas-induced hepatic failure. J Biol Chem. 281:221–228. 2006. View Article : Google Scholar : PubMed/NCBI
50.	Gonzalez-Rodriguez A, Escribano O, Alba J, Rondinone CM, Benito M and Valverde AM: Levels of protein tyrosine phosphatase 1B determine susceptibility to apoptosis in serum-deprived hepatocytes. J Cell Physiol. 212:76–88. 2007. View Article : Google Scholar : PubMed/NCBI
51.	Gu F, Nguyen DT, Stuible M, Dube N, Tremblay ML and Chevet E: Protein-tyrosine phosphatase 1B potentiates IRE1 signaling during endoplasmic reticulum stress. J Biol Chem. 279:49689–49693. 2004. View Article : Google Scholar : PubMed/NCBI
52.	Akasaki Y, Liu G, Matundan HH, et al: A peroxisome proliferator-activated receptor-gamma agonist, troglitazone, facilitates caspase-8 and -9 activities by increasing the enzymatic activity of protein-tyrosine phosphatase-1B on human glioma cells. J Biol Chem. 281:6165–6174. 2006. View Article : Google Scholar
53.	Iorio MV and Croce CM: microRNA involvement in human cancer. Carcinogenesis. 33:1126–1133. 2012. View Article : Google Scholar : PubMed/NCBI
54.	Dahiya N and Morin PJ: MicroRNAs in ovarian carcinomas. Endocr Relat Cancer. 17:F77–F89. 2010. View Article : Google Scholar : PubMed/NCBI
55.	Shih KK, Qin LX, Tanner EJ, et al: A microRNA survival signature (MiSS) for advanced ovarian cancer. Gynecol Oncol. 121:444–450. 2011. View Article : Google Scholar : PubMed/NCBI
56.	Giannakakis A, Sandaltzopoulos R, Greshock J, et al: miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther. 7:255–264. 2008. View Article : Google Scholar : PubMed/NCBI
57.	Tsuchiya S, Fujiwara T, Sato F, et al: MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1). J Biol Chem. 286:420–428. 2011. View Article : Google Scholar : PubMed/NCBI
58.	Li T, Cao H, Zhuang J, et al: Identification of miR-130a, miR-27b and miR-210 as serum biomarkers for atherosclerosis obliterans. Clin Chim Acta. 412:66–70. 2011. View Article : Google Scholar : PubMed/NCBI
59.	Puissegur MP, Mazure NM, Bertero T, et al: miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ. 18:465–478. 2011. View Article : Google Scholar : PubMed/NCBI
60.	Ramon LA, Braza-Boils A, Gilabert J, et al: microRNAs related to angiogenesis are dysregulated in endometrioid endometrial cancer. Hum Reprod. 27:3036–3045. 2012. View Article : Google Scholar : PubMed/NCBI
61.	Chen WY, Liu WJ, Zhao YP, et al: Induction, modulation and potential targets of miR-210 in pancreatic cancer cells. Hepatobiliary Pancreat Dis Int. 11:319–324. 2012. View Article : Google Scholar : PubMed/NCBI
62.	Favaro E, Ramachandran A, McCormick R, et al: MicroRNA-210 regulates mitochondrial free radical response to hypoxia and krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU. PLoS One. 5:e103452010. View Article : Google Scholar : PubMed/NCBI
63.	Nakada C, Tsukamoto Y, Matsuura K, et al: Overexpression of miR-210, a downstream target of HIF1alpha, causes centrosome amplification in renal carcinoma cells. J Pathol. 224:280–288. 2011. View Article : Google Scholar : PubMed/NCBI
64.	Noman MZ, Buart S, Romero P, et al: Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Cancer Res. 72:4629–4641. 2012. View Article : Google Scholar : PubMed/NCBI